arrow
R

Rangi Kandane-Rathnayake

monash university
H指数:28
被引数:2,322

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical characteristics and response to standard-of-care treatment in systemic lupus erythematosus patients with or without anti-ribonucleoprotein (RNP) antibodies: an Australian, multi-centre cohort study

系统性红斑狼疮患者中抗核糖核蛋白(RNP)抗体阳性与阴性患者的临床特征及对标准治疗方案的反应:一项澳大利亚、多中心队列研究

2026-05-110
OAAI
Mucocutaneous disease activity and damage accrual in systemic lupus erythematosus: analyses from the Asia-Pacific Lupus Collaboration longitudinal cohort study

黏膜皮肤疾病活动度和损伤累积在系统性红斑狼疮中的表现:亚太狼疮合作组织纵向队列研究的分析

2026-04-060
OAAI
Treatment patterns, treat-to-target goals and clinical outcomes of patients with active lupus nephritis: real-world evidence from a multicentre cohort study
2026-03-180
OAAI
Predictors of damage accrual by organ domain in systemic lupus erythematosus

系统性红斑狼疮中按器官领域累积损伤的预测因子

2025-12-010
OAAI
Prevalence, Determinants, and Outcomes of Low Disease Activity and Remission Attainment in Patients With Systemic Lupus Erythematosus That Is Clinically Active
2025-12-010
OAAI
Prevalence and outcomes of a pilot definition of severe refractory systemic lupus erythematosus: observations from a multinational Asia-Pacific cohort

严重难治性系统性红斑狼疮试点定义的患病率与结局:来自跨国亚太队列的观察

2025-08-180
PRE
Frequency and Determinants of Flare and Persistently Active Disease in a Large Multinational Prospective Lupus Cohort

系统性红斑狼疮大型跨国前瞻性队列中flare和持续性活动性疾病的频率与决定因素

2025-02-260
OAAI
Time trends of variability in disease activity in systemic lupus erythematosus
2025-02-120
OAAI
Longitudinal associations of flare and damage accrual in patients with systemic lupus erythematosus
2025-01-190
OAAI
Characterisation and outcomes of different subsets of low disease activity states in patients with systemic lupus erythematosus
2024-09-180
OAAI
Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study
2024-08-012
PRE
IMPACT OF TAPERING OF IMMUNOSUPPRESSIVE THERAPY OR GLUCOCORTICOIDS ON DAMAGE ACCRUAL AFTER ACHIEVING LOW DISEASE ACTIVITY OR REMISSION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: DATA FROM A LARGE MULTINATIONAL COHORT

系统性红斑狼疮患者达到低疾病活动度或缓解后,免疫抑制治疗或糖皮质激素减量的损伤累积影响:来自大型跨国队列的数据

2024-06-010
PRE
PREVALENCE AND OUTCOMES OF SEVERE REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): OBSERVATIONS FROM A MULTINATIONAL COHORT

系统性红斑狼疮(SLE)重症难治患者的患病率与结局:来自多国队列的观察

2024-06-010
PRE
CLINICAL CHARACTERISTICS AND RESPONSE TO STANDARD-OF-CARE IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH OR WITHOUT ANTI-RIBONUCLEOPROTEIN (RNP) ANTIBODIES

系统性红斑狼疮患者有无抗核糖核蛋白(RNP)抗体时的临床特征及对标准治疗的反应

2024-06-010
PRE
ERYTHROCYTE SEDIMENTATION RATE AS A BIOMARKER IN SLE

红细胞沉降率作为SLE的生物标志物

2024-06-010
PRE
PREDICTORS AND IMPACT OF DRUG SURVIVAL OF ANTI-MALARIAL AND IMMUNOSUPPRESSIVE THERAPIES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: DATA FROM A LARGE MULTINATIONAL COHORT

抗疟药和免疫抑制疗法药物生存的预测因素及影响:来自大型跨国队列的数据

2024-06-010
PRE
Comparison of Attainment and Protective Effects of Lupus Low Disease Activity State in Patients With Newly Diagnosed Versus Established Systemic Lupus Erythematosus
2024-03-152
PRE